Selective Inhibition of 11beta-Hydroxysteroiddehydrogenase-1 with BI 187004 in Patients with Type 2 Diabetes and Overweight or Obesity: Safety, Pharmacokinetics, and Pharmacodynamics After Multiple Dosing Over 14 Days

Conclusions BI 187004 was safe and well tolerated over 14 days and could
be dosed once daily. Targeted 11beta-HSD1 enzyme inhibition
of≥80% could be shown for BI 187004 doses≥40 mg.
This dose should be targeted in further studies to test blood glucose lowering
in patients with type 2 diabetes and overweight or obesity. [...] Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyArticle in Thieme eJournals: Table of contents  |  Abstract  |  open access Full text

Source: Experimental and Clinical Endocrinology and Diabetes - November 7, 2022 Category: Endocrinology Authors: Bianzano, Susanna Schepers, Cornelia Wolff, Michael Heise, Tim Plum-Moerschel, Leona Tags: Article Source Type: research